BB BIOTECH AG portfolio
Latest available portfolio: Q1 2019 · Holdings as of · Filed · $3,977,857,000 in Form 13F holdings
See latest portfolio changesQuarterly portfolio filings
Choose a quarter to see holdings and changes. Newer portfolio dates appear first.
Estimated additions and reductions value share changes at filing-derived prices; they are not actual trade proceeds or costs.
| Quarter | Holdings | SEC-reported value | Est. additions | Est. reductions | Est. net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $0 | 13F-NT | 14 Aug 2026, 11:53 | |||||
| Q1 2026 | $0 | 13F-NT | 14 May 2026, 17:53 | |||||
| Q4 2025 | $0 | 13F-NT | 17 Feb 2026, 16:00 | |||||
| Q3 2025 | $0 | 13F-NT | 14 Nov 2025, 17:08 | |||||
| Q2 2025 | $0 | 13F-NT | 14 Aug 2025, 15:23 | |||||
| Q1 2025 | $0 | 13F-NT | 14 May 2025, 16:46 | |||||
| Q4 2024 | $0 | 13F-NT | 14 Feb 2025, 16:18 | |||||
| Q3 2024 | $0 | 13F-NT | 14 Nov 2024, 17:23 | |||||
| Q2 2024 | $0 | 13F-NT | 14 Aug 2024, 14:11 | |||||
| Q1 2024 | $0 | 13F-NT | 15 May 2024, 15:07 | |||||
| Q4 2023 | $0 | 13F-NT | 14 Feb 2024, 12:17 | |||||
| Q3 2023 | 0 | $0 | 13F-NT | 14 Nov 2023, 13:59 | ||||
| Q2 2023 | 0 | $0 | 13F-NT | 14 Aug 2023, 12:58 | ||||
| Q1 2023 | 0 | $0 | 13F-NT | 15 May 2023, 10:31 | ||||
| Q4 2022 | 0 | $0 | 13F-NT | 14 Feb 2023, 11:51 | ||||
| Q3 2022 | 0 | $0 | 13F-NT | 14 Nov 2022, 13:01 | ||||
| Q2 2022 | 0 | $0 | 13F-NT | 11 Aug 2022, 11:01 | ||||
| Q1 2022 | 0 | $0 | 13F-NT | 13 May 2022, 16:24 | ||||
| Q4 2021 | 0 | $0 | 13F-NT | 10 Feb 2022, 09:57 | ||||
| Q3 2021 | 0 | $0 | 13F-NT | 12 Nov 2021, 05:35 | ||||
| Q2 2021 | 0 | $0 | 13F-NT | 12 Aug 2021, 12:54 | ||||
| Q1 2021 | 0 | $0 | 13F-NT | 11 May 2021, 17:49 | ||||
| Q4 2020 | 0 | $0 | 13F-NT | 16 Feb 2021, 08:10 | ||||
| Q3 2020 | 0 | $0 | 13F-NT | 16 Nov 2020, 15:25 | ||||
| Q2 2020 | 0 | $0 | 13F-NT | 13 Aug 2020, 16:07 |
Showing 1-25 of 51 filings.
Manager details and filing context
- Latest 13F filing
- Q2 2026 - 14 Aug 2026
- Largest 13F holdings
-
IONS INCY NBIX VRTX SAGE CELG AGIO ALXN ALNY ESPR RDUS HALO
+8 more
ARGX MRNA MYOV ICPT GILD NKTR EXEL AKCA - Form 13F summary
-
- BB BIOTECH AG Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- BB BIOTECH AG reported 35 equity holdings with a total reported market value of $3,977,857,000 for Q1 2019. Top reported holdings included IONS, INCY, NBIX, VRTX, and SAGE. <a href="/investor/0001674546-bellevue-group-ag">Bellevue Group AG</a> is reporting for BB BIOTECH AG.
- Manager signature
- Ivo Betschart - SIGNING AUTHORITY
- Manager location
- Schaffhausen
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Bellevue Group AG is reporting for BB BIOTECH AG:
| Name | Holdings Value | Location | File Number |
|---|---|---|---|
| Bellevue Group AG | $4,752,644,375 | Zurich | 028-17462 |
Holdings Value